APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hyperimmune Globulins

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Selected research

Industry Research

Hyperimmune Globulins Industry Research Report 2026

Report ID 174000980526 December 2025123 pages

Choose your research edition.

Industry ResearchHyperimmune Globulins Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hyperimmune Globulins Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Hyperimmune Globulins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hyperimmune Globulins Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Hyperimmune Globulins Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.

Read the full market overview

Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.

In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

Report Scope

This report quantifies the global Hyperimmune Globulins market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Hyperimmune Globulins Market by Company

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Hyperimmune Globulins Segment by Type

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Other

Hyperimmune Globulins Segment by Application

Government Institutions

Private Sector

Other

Hyperimmune Globulins Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Globulins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Globulins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Globulins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Hyperimmune Globulins by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Hyperimmune Globulins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hyperimmune Globulins Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Hyperimmune Globulins Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Hyperimmune Globulins Sales Market Share by Manufacturers (2021-2026) Table 8. Global Hyperimmune Globulins Revenue of Manufacturers (2021-2026) Table 9. Global Hyperimmune Globulins Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Hyperimmune Globulins Average Price (USD/Unit) of Manufacturers (2021-2026) Table 11. Global Hyperimmune Globulins Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Hyperimmune Globulins, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Hyperimmune Globulins, Product Type & Application Table 14. Global Hyperimmune Globulins Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Hyperimmune Globulins by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. CSL Behring Company Information Table 19. CSL Behring Business Overview Table 20. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 21. CSL Behring Hyperimmune Globulins Product Portfolio Table 22. CSL Behring Recent Developments Table 23. Grifols Company Information Table 24. Grifols Business Overview Table 25. Grifols Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 26. Grifols Hyperimmune Globulins Product Portfolio Table 27. Grifols Recent Developments Table 28. Biotest Company Information Table 29. Biotest Business Overview Table 30. Biotest Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 31. Biotest Hyperimmune Globulins Product Portfolio Table 32. Biotest Recent Developments Table 33. Kedrion Company Information Table 34. Kedrion Business Overview Table 35. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 36. Kedrion Hyperimmune Globulins Product Portfolio Table 37. Kedrion Recent Developments Table 38. CBPO Company Information Table 39. CBPO Business Overview Table 40. CBPO Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 41. CBPO Hyperimmune Globulins Product Portfolio Table 42. CBPO Recent Developments Table 43. Emergent (Cangene) Company Information Table 44. Emergent (Cangene) Business Overview Table 45. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 46. Emergent (Cangene) Hyperimmune Globulins Product Portfolio Table 47. Emergent (Cangene) Recent Developments Table 48. Kamada Company Information Table 49. Kamada Business Overview Table 50. Kamada Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 51. Kamada Hyperimmune Globulins Product Portfolio Table 52. Kamada Recent Developments Table 53. CNBG Company Information Table 54. CNBG Business Overview Table 55. CNBG Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 56. CNBG Hyperimmune Globulins Product Portfolio Table 57. CNBG Recent Developments Table 58. Hualan Bio Company Information Table 59. Hualan Bio Business Overview Table 60. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 61. Hualan Bio Hyperimmune Globulins Product Portfolio Table 62. Hualan Bio Recent Developments Table 63. Shanghai RAAS Company Information Table 64. Shanghai RAAS Business Overview Table 65. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 66. Shanghai RAAS Hyperimmune Globulins Product Portfolio Table 67. Shanghai RAAS Recent Developments Table 68. Sichuan Yuanda Shuyang Company Information Table 69. Sichuan Yuanda Shuyang Business Overview Table 70. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 71. Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio Table 72. Sichuan Yuanda Shuyang Recent Developments Table 73. ADMA Biologics Company Information Table 74. ADMA Biologics Business Overview Table 75. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. ADMA Biologics Hyperimmune Globulins Product Portfolio Table 77. ADMA Biologics Recent Developments Table 78. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Hyperimmune Globulins Sales by Region (2021-2026) & (K Units) Table 80. Global Hyperimmune Globulins Sales Market Share by Region (2021-2026) Table 81. Global Hyperimmune Globulins Sales by Region (2027-2032) & (K Units) Table 82. Global Hyperimmune Globulins Sales Market Share by Region (2027-2032) Table 83. Global Hyperimmune Globulins Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Hyperimmune Globulins Revenue Market Share by Region (2021-2026) Table 85. Global Hyperimmune Globulins Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Hyperimmune Globulins Revenue Market Share by Region (2027-2032) Table 87. North America Hyperimmune Globulins Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 89. North America Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 90. North America Hyperimmune Globulins Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Hyperimmune Globulins Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Hyperimmune Globulins Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 94. Europe Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 95. Europe Hyperimmune Globulins Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Hyperimmune Globulins Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Hyperimmune Globulins Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 99. Asia Pacific Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 100. Asia Pacific Hyperimmune Globulins Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Hyperimmune Globulins Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Hyperimmune Globulins Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 104. South America Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 105. South America Hyperimmune Globulins Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Hyperimmune Globulins Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Hyperimmune Globulins Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 109. Middle East and Africa Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 110. Middle East and Africa Hyperimmune Globulins Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Hyperimmune Globulins Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Hyperimmune Globulins Sales by Type (2021-2026) & (K Units) Table 113. Global Hyperimmune Globulins Sales by Type (2027-2032) & (K Units) Table 114. Global Hyperimmune Globulins Sales Market Share by Type (2021-2026) Table 115. Global Hyperimmune Globulins Sales Market Share by Type (2027-2032) Table 116. Global Hyperimmune Globulins Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Hyperimmune Globulins Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Hyperimmune Globulins Revenue Market Share by Type (2021-2026) Table 119. Global Hyperimmune Globulins Revenue Market Share by Type (2027-2032) Table 120. Global Hyperimmune Globulins Price by Type (2021-2026) & (USD/Unit) Table 121. Global Hyperimmune Globulins Price by Type (2027-2032) & (USD/Unit) Table 122. Global Hyperimmune Globulins Sales by Application (2021-2026) & (K Units) Table 123. Global Hyperimmune Globulins Sales by Application (2027-2032) & (K Units) Table 124. Global Hyperimmune Globulins Sales Market Share by Application (2021-2026) Table 125. Global Hyperimmune Globulins Sales Market Share by Application (2027-2032) Table 126. Global Hyperimmune Globulins Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Hyperimmune Globulins Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Hyperimmune Globulins Revenue Market Share by Application (2021-2026) Table 129. Global Hyperimmune Globulins Revenue Market Share by Application (2027-2032) Table 130. Global Hyperimmune Globulins Price by Application (2021-2026) & (USD/Unit) Table 131. Global Hyperimmune Globulins Price by Application (2027-2032) & (USD/Unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Hyperimmune Globulins Distributors List Table 135. Hyperimmune Globulins Customers List Table 136. Hyperimmune Globulins Industry Trends Table 137. Hyperimmune Globulins Industry Drivers Table 138. Hyperimmune Globulins Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Hyperimmune Globulins Product Image Figure 5. Global Hyperimmune Globulins Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Hyperimmune Globulins Market Size (2021-2032) & (US$ Million) Figure 7. Global Hyperimmune Globulins Sales (2021-2032) & (K Units) Figure 8. Global Hyperimmune Globulins Average Price (USD/Unit) & (2021-2032) Figure 9. Hepatitis B Immunoglobulins Product Image Figure 10. Rabies Immunoglobulins Product Image Figure 11. Tetanus Immunoglobulins Product Image Figure 12. Rho(D) Immunoglobulins Product Image Figure 13. Other Product Image Figure 14. Government Institutions Product Image Figure 15. Private Sector Product Image Figure 16. Other Product Image Figure 17. Global Hyperimmune Globulins Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Hyperimmune Globulins, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Hyperimmune Globulins Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Hyperimmune Globulins Sales by Region in 2025 Figure 23. Global Hyperimmune Globulins Revenue by Region in 2025 Figure 24. North America Hyperimmune Globulins Market Size by Country in 2025 Figure 25. North America Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 26. North America Hyperimmune Globulins Revenue Market Share by Country (2021-2032) Figure 27. United States Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Hyperimmune Globulins Market Size by Country in 2025 Figure 31. Europe Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 32. Europe Hyperimmune Globulins Revenue Market Share by Country (2021-2032) Figure 33. Germany Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Hyperimmune Globulins Market Size by Country in 2025 Figure 44. Asia Pacific Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Hyperimmune Globulins Revenue Market Share by Country (2021-2032) Figure 46. China Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Hyperimmune Globulins Market Size by Country in 2025 Figure 55. South America Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 56. South America Hyperimmune Globulins Revenue Market Share by Country (2021-2032) Figure 57. Brazil Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Hyperimmune Globulins Market Size by Country in 2025 Figure 61. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2021-2032) Figure 63. Egypt Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Hyperimmune Globulins Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Hyperimmune Globulins Sales Market Share by Type (2021-2032) Figure 69. Global Hyperimmune Globulins Revenue Market Share by Type (2021-2032) Figure 70. Global Hyperimmune Globulins Price (USD/Unit) by Type (2021-2032) Figure 71. Global Hyperimmune Globulins Sales Market Share by Application (2021-2032) Figure 72. Global Hyperimmune Globulins Revenue Market Share by Application (2021-2032) Figure 73. Global Hyperimmune Globulins Price (USD/Unit) by Application (2021-2032) Figure 74. Hyperimmune Globulins Value Chain Figure 75. Hyperimmune Globulins Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Hyperimmune Globulins Industry Opportunities and Challenges

Scope & coverage.

Types
  • Hepatitis B Immunoglobulins
  • Rabies Immunoglobulins
  • Tetanus Immunoglobulins
  • Rho(D) Immunoglobulins
  • Other
Applications
  • Government Institutions
  • Private Sector
  • Other
Companies covered
  • CSL Behring
  • Grifols
  • Biotest
  • Kedrion
  • CBPO
  • Emergent (Cangene)
  • Kamada
  • CNBG
  • Hualan Bio
  • Shanghai RAAS
  • Sichuan Yuanda Shuyang
  • ADMA Biologics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Hyperimmune Globulins Market Size (2021-2032)
  4. 2.2.2 Global Hyperimmune Globulins Sales (2021-2032)
  5. 2.2.3 Global Hyperimmune Globulins Market Average Price (2021-2032)
  6. 2.3 Hyperimmune Globulins by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Hepatitis B Immunoglobulins
  9. 2.3.3 Rabies Immunoglobulins
  10. 2.3.4 Tetanus Immunoglobulins
  11. 2.3.5 Rho(D) Immunoglobulins
  12. 2.3.6 Other
  13. 2.4 Hyperimmune Globulins by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Government Institutions
  16. 2.4.3 Private Sector
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Hyperimmune Globulins Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Hyperimmune Globulins Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Hyperimmune Globulins Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Hyperimmune Globulins Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Hyperimmune Globulins Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Hyperimmune Globulins, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Hyperimmune Globulins, Product Type & Application
  8. 3.8 Global Manufacturers of Hyperimmune Globulins, Established Date
  9. 3.9 Global Hyperimmune Globulins Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 CSL Behring
  2. 4.1.1 CSL Behring Company Information
  3. 4.1.2 CSL Behring Business Overview
  4. 4.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 CSL Behring Hyperimmune Globulins Product Portfolio
  6. 4.1.5 CSL Behring Recent Developments
  7. 4.2 Grifols
  8. 4.2.1 Grifols Company Information
  9. 4.2.2 Grifols Business Overview
  10. 4.2.3 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Grifols Hyperimmune Globulins Product Portfolio
  12. 4.2.5 Grifols Recent Developments
  13. 4.3 Biotest
  14. 4.3.1 Biotest Company Information
  15. 4.3.2 Biotest Business Overview
  16. 4.3.3 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Biotest Hyperimmune Globulins Product Portfolio
  18. 4.3.5 Biotest Recent Developments
  19. 4.4 Kedrion
  20. 4.4.1 Kedrion Company Information
  21. 4.4.2 Kedrion Business Overview
  22. 4.4.3 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Kedrion Hyperimmune Globulins Product Portfolio
  24. 4.4.5 Kedrion Recent Developments
  25. 4.5 CBPO
  26. 4.5.1 CBPO Company Information
  27. 4.5.2 CBPO Business Overview
  28. 4.5.3 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 CBPO Hyperimmune Globulins Product Portfolio
  30. 4.5.5 CBPO Recent Developments
  31. 4.6 Emergent (Cangene)
  32. 4.6.1 Emergent (Cangene) Company Information
  33. 4.6.2 Emergent (Cangene) Business Overview
  34. 4.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio
  36. 4.6.5 Emergent (Cangene) Recent Developments
  37. 4.7 Kamada
  38. 4.7.1 Kamada Company Information
  39. 4.7.2 Kamada Business Overview
  40. 4.7.3 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Kamada Hyperimmune Globulins Product Portfolio
  42. 4.7.5 Kamada Recent Developments
  43. 4.8 CNBG
  44. 4.8.1 CNBG Company Information
  45. 4.8.2 CNBG Business Overview
  46. 4.8.3 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 CNBG Hyperimmune Globulins Product Portfolio
  48. 4.8.5 CNBG Recent Developments
  49. 4.9 Hualan Bio
  50. 4.9.1 Hualan Bio Company Information
  51. 4.9.2 Hualan Bio Business Overview
  52. 4.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio
  54. 4.9.5 Hualan Bio Recent Developments
  55. 4.10 Shanghai RAAS
  56. 4.10.1 Shanghai RAAS Company Information
  57. 4.10.2 Shanghai RAAS Business Overview
  58. 4.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio
  60. 4.10.5 Shanghai RAAS Recent Developments
  61. 4.11 Sichuan Yuanda Shuyang
  62. 4.11.1 Sichuan Yuanda Shuyang Company Information
  63. 4.11.2 Sichuan Yuanda Shuyang Business Overview
  64. 4.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio
  66. 4.11.5 Sichuan Yuanda Shuyang Recent Developments
  67. 4.12 ADMA Biologics
  68. 4.12.1 ADMA Biologics Company Information
  69. 4.12.2 ADMA Biologics Business Overview
  70. 4.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio
  72. 4.12.5 ADMA Biologics Recent Developments
5 Global Hyperimmune Globulins Market Scenario by Region
  1. 5.1 Global Hyperimmune Globulins Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Hyperimmune Globulins Sales by Region: 2021-2032
  3. 5.2.1 Global Hyperimmune Globulins Sales by Region: 2021-2026
  4. 5.2.2 Global Hyperimmune Globulins Sales by Region: 2027-2032
  5. 5.3 Global Hyperimmune Globulins Revenue by Region: 2021-2032
  6. 5.3.1 Global Hyperimmune Globulins Revenue by Region: 2021-2026
  7. 5.3.2 Global Hyperimmune Globulins Revenue by Region: 2027-2032
  8. 5.4 North America Hyperimmune Globulins Market Facts & Figures by Country
  9. 5.4.1 North America Hyperimmune Globulins Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Hyperimmune Globulins Sales by Country (2021-2032)
  11. 5.4.3 North America Hyperimmune Globulins Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Hyperimmune Globulins Market Facts & Figures by Country
  16. 5.5.1 Europe Hyperimmune Globulins Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Hyperimmune Globulins Sales by Country (2021-2032)
  18. 5.5.3 Europe Hyperimmune Globulins Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Hyperimmune Globulins Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Hyperimmune Globulins Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Hyperimmune Globulins Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Hyperimmune Globulins Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Hyperimmune Globulins Market Facts & Figures by Country
  41. 5.7.1 South America Hyperimmune Globulins Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Hyperimmune Globulins Sales by Country (2021-2032)
  43. 5.7.3 South America Hyperimmune Globulins Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Hyperimmune Globulins Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Hyperimmune Globulins Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Hyperimmune Globulins Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Hyperimmune Globulins Sales by Type (2021-2032)
  2. 6.1.1 Global Hyperimmune Globulins Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Hyperimmune Globulins Sales Market Share by Type (2021-2032)
  4. 6.2 Global Hyperimmune Globulins Revenue by Type (2021-2032)
  5. 6.2.1 Global Hyperimmune Globulins Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Hyperimmune Globulins Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Hyperimmune Globulins Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Hyperimmune Globulins Sales by Application (2021-2032)
  2. 7.1.1 Global Hyperimmune Globulins Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Hyperimmune Globulins Sales Market Share by Application (2021-2032)
  4. 7.2 Global Hyperimmune Globulins Revenue by Application (2021-2032)
  5. 7.2.1 Global Hyperimmune Globulins Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Hyperimmune Globulins Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Hyperimmune Globulins Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Hyperimmune Globulins Value Chain Analysis
  2. 8.1.1 Hyperimmune Globulins Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Hyperimmune Globulins Production Mode & Process
  5. 8.2 Hyperimmune Globulins Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Hyperimmune Globulins Distributors
  8. 8.2.3 Hyperimmune Globulins Customers
9 Global Hyperimmune Globulins Analyzing Market Dynamics
  1. 9.1 Hyperimmune Globulins Industry Trends
  2. 9.2 Hyperimmune Globulins Industry Drivers
  3. 9.3 Hyperimmune Globulins Industry Opportunities and Challenges
  4. 9.4 Hyperimmune Globulins Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst